Passage Bio Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta 1.13
Market capitalization 64.92M
Operating cash flow -124.96M
ESG Scores unknown

Company description

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 212k 398k 4.59M 2.2M
Total Cashflows From Investing Activities -2.54M -1.69M -172.11M -45.81M
Net Borrowings
Total Cash From Financing Activities 45.97M 175.6M 228.75M 166.66M
Change To Operating Activities -8.74M -6.34M 9.85M 9.22M
Issuance Of Stock 176k 176k 228.75M 166.99M
Net Income -12.77M -45.63M -112.23M -185.39M
Change In Cash 24.86M 134.01M -23.87M -6.04M
Effect Of Exchange Rate
Total Cash From Operating Activities -18.57M -39.9M -80.52M -126.88M
Depreciation 134k 134k 800k 1.54M
Change To Account Receivables
Other Cashflows From Financing Activities -1.78M -763k -338k -338k
Change To Netincome 2.73M 11.55M 16.47M 45.54M
Capital Expenditures -28k -1.19M -1.15M -17.64M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 9.17M 29.74M 81.79M 117.67M
Income Before Tax -12.77M -45.63M -112.23M -185.39M
Net Income -12.77M -45.63M -112.23M -185.39M
Selling General Administrative 928k 6.95M 30.11M 60.06M
Gross Profit
Ebit -10.1M -36.69M -111.9M -177.73M
Operating Income -10.1M -36.69M -111.9M -177.73M
Interest Expense
Income Tax Expense
Total Revenue
Cost Of Revenue
Total Other Income ExpenseNet -2.67M -8.95M -330k -7.66M
Net Income From Continuing Ops -12.77M -45.63M -112.23M -185.39M
Net Income Applicable To Common Shares -12.77M -45.63M -112.23M -185.39M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 2.52M 4.26M 23.29M 36.42M
Total Stockholder Equity -12.17M -56.25M 304.71M 318.66M
Other Current Liabilities 7k 46k 541k 661k
Total Assets 33.46M 178.61M 328.01M 355.08M
Common Stock 2k 4k 5k
Other Current Assets 8.44M 6.75M 10.96M 7.57M
Retained Earnings -13.03M -58.66M -170.9M -356.28M
Treasury Stock -12k -413k
Cash 24.86M 158.87M 135M 128.97M
Total Current Liabilities 307k 3.68M 21.18M 29.5M
Other Stockholder Equity -12k -413k
Property, Plant, and Equipment 28k 1.09M 2.79M 23.81M
Total Current Assets 33.4M 165.78M 317.18M 325.07M
Net Tangible Assets -12.17M -56.25M 304.71M 318.66M
Net Receivables 300k
Accounts Payable 212k 629k 5.26M 9.45M


Insider Transactions

Here are the insider transactions of stock shares related to Passage Bio Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
FOTOPOULOS ALEXANDROSSale at price 1.33 per share.D2022-11-22Chief Technology Officer3.72k
FOTOPOULOS ALEXANDROSD2022-11-22Chief Technology Officer12.5k
TOERNSEN MONIKA MARIASale at price 1.51 per share.D2022-09-19Officer1.68k
TOERNSEN MONIKA MARIAD2022-09-15Officer5k
ORBIMED ADVISORS, L.L.C.Purchase at price 1.93 - 1.94 per share.I2022-05-04Beneficial Owner of more than 10% of a Class of Security525k
GOLDSMITH BRUCE APurchase at price 3.15 per share.D2022-03-21Chief Executive Officer10k
ORBIMED ADVISORS, L.L.C.Purchase at price 5.42 per share.I2022-01-20Beneficial Owner of more than 10% of a Class of Security369.1k
ORBIMED ADVISORS, L.L.C.Purchase at price 5.00 per share.I2022-01-20Beneficial Owner of more than 10% of a Class of Security50.8k
ORBIMED ADVISORS, L.L.C.Purchase at price 5.11 - 5.60 per share.I2022-01-19Beneficial Owner of more than 10% of a Class of Security168.3k
ORBIMED ADVISORS, L.L.C.Purchase at price 5.52 - 5.65 per share.I2022-01-13Beneficial Owner of more than 10% of a Class of Security150k
QUIGLEY JILL M.Conversion of Exercise of derivative security at price 0.23 per share.D2021-12-08Chief Operating Officer71.97k
MORRIS RICHARD STEVENPurchase at price 13.82 per share.D2021-05-21Chief Financial Officer2.17k
GOLDSMITH BRUCE APurchase at price 13.12 per share.D2021-05-21Chief Executive Officer2k
ROMANO GARYSale at price 20.95 - 21.86 per share.D2021-03-15Officer10k
ROMANO GARYConversion of Exercise of derivative security at price 8.07 per share.D2021-03-15Officer10k
QUIGLEY JILL M.Sale at price 30.01 per share.D2021-01-20Chief Operating Officer1.3k
QUIGLEY JILL M.Sale at price 30.10 per share.D2021-01-14Chief Operating Officer16.3k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Passage Bio Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Passage Bio Inc

Here is the result of two systematic investment strategies applied to Passage Bio Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Passage Bio Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Passage Bio Inc:

Passage Bio Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -27.92% on the backtest period.

Performance at glance

Performance

-27.92 %

Latent gain

-280.07 $

Invested capital

1002.99 $

Annualized return

-17.23 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Passage Bio Inc

This is the result of two momentum investment strategies applied to Passage Bio Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Passage Bio Inc

The following chart shows all the entries opened by the momentum investment system on Passage Bio Inc:

Passage Bio Inc momentum entries
  • The first momentum investment strategy would give -25.32% of return on Passage Bio Inc. That represents -505.99$ of latent gain with 1998.47$ of employed capital.
  • The second momentum investment strategy would give -19.95% of return on Passage Bio Inc. That represents -252.75$ of latent gain with 1267.17$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-25.32 %

Latent gain

-505.99 $

Invested capital

1998.47 $

Annualized return

-0.0 %
Performance at glance (2Q Momentum)

Performance

-19.95 %

Latent gain

-252.75 $

Invested capital

1267.17 $

Annualized return

-17.5 %

Momentum equity curve on Passage Bio Inc

The following chart shows the equity curve of the two momentum strategies applied to Passage Bio Inc:

Passage Bio Inc momentum equity

Note: the dividends potentially given by Passage Bio Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Passage Bio Inc

The following chart shows the employed capital evolution of the two momentum strategies on Passage Bio Inc since the beginning:

Passage Bio Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Passage Bio Inc

Buy the dip entry openings on Passage Bio Inc

Passage Bio Inc

The performance achieved by the robo-advisor on Passage Bio Inc is 0%. That represents 0.0$ of latent gain with 0.0$ of employed capital. The following chart shows Passage Bio Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Passage Bio Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

0 %

Latent gain

0.0 $

Invested capital

0.0 $

Annualized return

-0.0 %

Equity curve of the strategy applied to Passage Bio Inc

The following chart shows the result of the investment strategy applied to Passage Bio Inc:

Passage Bio Inc

Note: the dividends potentially given by Passage Bio Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Passage Bio Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Passage Bio Inc:

Passage Bio Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Passage Bio Inc

In this section, I will compare the three previous investment strategies applied to Passage Bio Inc.

Equity curve comparison on Passage Bio Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Passage Bio Inc investment strategy comparison

Employed capital comparison on Passage Bio Inc

Passage Bio Inc investment comparison

Performance comparison on Passage Bio Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -27.92% -280.07$ 1002.99$ -17.23%
Momentum 1 quarter -25.32% -505.99$ 1998.47$ -18.35%
Momentum 2 quarters -19.95% -252.75$ 1267.17$ -17.5%
Non-directional 0% 0.0$ 0.0$ -0.0%
Annualized return comparison

Automatic investment

-17.23 %

Momentum 1Q

-17.5 %

Momentum 2Q

-17.5 %

Non-directional

-0.0 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Passage Bio Inc:

Positive correlations

Most correlated stocks this year

  • Passage Bio Inc

  • Most correlated stocks last 3 months

  • DA YU FIN
  • SEA HOLDINGS
  • Passage Bio Inc
  • HK&S HOTELS
  • EMPEROR WATCH&J

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • JADASON^

  • Note: The algorithm computes the probability of correlation between Passage Bio Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Passage Bio Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Passage Bio Inc
    Country United States
    City Philadelphia
    Address One Commerce Square
    Phone 267 866 0311
    Website www.passagebio.com
    FullTime employees 133
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker PASG
    Market www.nasdaq.com

    Passage Bio Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown